Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Soundtrack-E: Surovatamig in Mature B-Cell Malignancies
NCT06564038Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2025
- Primary completion
- May 2030
- Modality
- Bispecific Antibodies, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 13
01
Overview
A Phase 2 trial of surovatamig in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), B-cell non-Hodgkin lymphoma, sponsored by AstraZeneca. Started Jan 2025; status: recruiting.
02
Drugs
surovatamig
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06564038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06564038.